Overview

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Status:
Terminated
Trial end date:
2018-10-26
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.
Collaborator:
Tigermed Consulting Co., Ltd